1
|
Gall E, Pezel T, Lattuca B, Hamzi K, Puymirat E, Piliero N, Deney A, Fauvel C, Aboyans V, Schurtz G, Bouleti C, Fabre J, El Ouahidi A, Thuaire C, Millischer D, Noirclerc N, Delmas C, Roubille F, Dillinger JG, Henry P. Profile of patients hospitalized in intensive cardiac care units in France: ADDICT-ICCU registry. Arch Cardiovasc Dis 2024; 117:195-203. [PMID: 38418306 DOI: 10.1016/j.acvd.2023.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2023] [Revised: 12/12/2023] [Accepted: 12/13/2023] [Indexed: 03/01/2024]
Abstract
BACKGROUND Intensive cardiac care units (ICCU) were initially developed to monitor ventricular arrhythmias after myocardial infarction. In recent decades, ICCU have diversified their activities. AIM To determine the type of patients hospitalized in ICCU in France. METHODS We analysed the characteristics of patients enrolled in the ADDICT-ICCU registry (NCT05063097), a prospective study of consecutive patients admitted to ICCU in 39 centres throughout France from 7th-22nd April 2021. In-hospital major adverse events (MAE) (death, resuscitated cardiac arrest and cardiogenic shock) were recorded. RESULTS Among 1499 patients (median age 65 [interquartile range 54-74] years, 69.6% male, 21.7% diabetes mellitus, 64.7% current or previous smokers), 34.9% had a history of coronary artery disease, 11.7% atrial fibrillation and 5.2% cardiomyopathy. The most frequent reason for admission to ICCU was acute coronary syndromes (ACS; 51.5%), acute heart failure (AHF; 14.1%) and unexplained chest pain (6.8%). An invasive procedure was performed in 36.2%. "Advanced" ICCU therapies were required for 19.9% of patients (intravenous diuretics 18.4%, non-invasive ventilation 6.1%, inotropic drugs 2.3%). No invasive procedures or advanced therapies were required in 44.1%. Cardiac computed tomography or magnetic resonance imaging was carried out in 12.3% of patients. The median length of ICCU hospitalization was 2.0 (interquartile range 1.0-4.0) days. The mean rate of MAE was 4.5%, and was highest in patients with AHF (10.4%). CONCLUSIONS ACS remains the main cause of admissions to ICCU, with most having a low rate of in-hospital MAE. Most patients experience a brief stay in ICCU before being discharged home. AHF is associated with highest death rate and with higher resource consumption.
Collapse
Affiliation(s)
- Emmanuel Gall
- Department of Cardiology, hôpital Lariboisière, Assistance publique-Hôpitaux de Paris, University of Paris, Inserm U-942, 10, rue Ambroise-Paré, 75010 Paris, France
| | - Théo Pezel
- Department of Cardiology, hôpital Lariboisière, Assistance publique-Hôpitaux de Paris, University of Paris, Inserm U-942, 10, rue Ambroise-Paré, 75010 Paris, France
| | - Benoît Lattuca
- Department of Cardiology, Nîmes University Hospital, Montpellier University, Nîmes, France
| | - Kenza Hamzi
- Department of Cardiology, hôpital Lariboisière, Assistance publique-Hôpitaux de Paris, University of Paris, Inserm U-942, 10, rue Ambroise-Paré, 75010 Paris, France
| | - Etienne Puymirat
- Department of Cardiology, hôpital européen Georges-Pompidou (HEGP), Paris, France
| | - Nicolas Piliero
- Department of Cardiology, CHU de Grenoble-Alpes, Grenoble, France
| | - Antoine Deney
- Cardiac Care Unit, Rangueil University Hospital, Toulouse, France
| | - Charles Fauvel
- Department of Cardiology, CHU de Rouen, University, UNIROUEN, U1096, 76000 Rouen, France
| | - Victor Aboyans
- Dupuytren University Hospital, Inserm 1094, Limoges, France
| | - Guillaume Schurtz
- Department of Cardiology, University Hospital of Lille, Lille, France
| | | | - Julien Fabre
- Department of Cardiology, University Hospital of Martinique, 97261 Fort-de-France, France
| | - Amine El Ouahidi
- Department of Cardiology, University Hospital of Brest, 29609 Brest cedex, France
| | - Christophe Thuaire
- Department of Cardiology, centre hospitalier de Chartres, 28630 Le Coudray, France
| | - Damien Millischer
- Department of Cardiology, hôpital Montfermeil, 93370 Montfermeil, France
| | - Nathalie Noirclerc
- Department of Cardiology, centre hospitalier Annecy-Genevois, 1, avenue de l'Hôpital, 74370 Epagny Metz-Tessy, France
| | - Clément Delmas
- Intensive Cardiac Care Unit, Rangueil University Hospital, Toulouse, France
| | - François Roubille
- Department of Cardiology, INI-CRT, CHU de Montpellier, PhyMedExp, université de Montpellier, Inserm, CNRS, 3429 Montpellier, France
| | - Jean-Guillaume Dillinger
- Department of Cardiology, hôpital Lariboisière, Assistance publique-Hôpitaux de Paris, University of Paris, Inserm U-942, 10, rue Ambroise-Paré, 75010 Paris, France
| | - Patrick Henry
- Department of Cardiology, hôpital Lariboisière, Assistance publique-Hôpitaux de Paris, University of Paris, Inserm U-942, 10, rue Ambroise-Paré, 75010 Paris, France.
| |
Collapse
|
2
|
Pezel T, Dillinger JG, Trimaille A, Delmas C, Piliero N, Bouleti C, Pommier T, El Ouahidi A, Andrieu S, Lattuca B, Rossanaly Vasram R, Fard D, Noirclerc N, Bonnet G, Goralski M, Elbaz M, Deney A, Schurtz G, Docq C, Roubille F, Fauvel C, Bochaton T, Aboyans V, Boccara F, Puymirat E, Batisse A, Steg G, Vicaut E, Henry P. Prevalence and impact of recreational drug use in patients with acute cardiovascular events. Heart 2023; 109:1608-1616. [PMID: 37582633 DOI: 10.1136/heartjnl-2023-322520] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Accepted: 04/26/2023] [Indexed: 08/17/2023] Open
Abstract
OBJECTIVE While recreational drug use is a risk factor for cardiovascular events, its exact prevalence and prognostic impact in patients admitted for these events are not established. We aimed to assess the prevalence of recreational drug use and its association with in-hospital major adverse events (MAEs) in patients admitted to intensive cardiac care units (ICCU). METHODS In the Addiction in Intensive Cardiac Care Units (ADDICT-ICCU) study, systematic screening for recreational drugs was performed by prospective urinary testing all patients admitted to ICCU in 39 French centres from 7 to 22 April 2021. The primary outcome was prevalence of recreational drug detection. In-hospital MAEs were defined by death, resuscitated cardiac arrest, or haemodynamic shock. RESULTS Of 1499 consecutive patients (63±15 years, 70% male), 161 (11%) had a positive test for recreational drugs (cannabis 9.1%, opioids 2.1%, cocaine 1.7%, amphetamines 0.7%, 3,4-methylenedioxymethamphetamine (MDMA) 0.6%). Only 57% of these patients declared recreational drug use. Patients who used recreational drugs exhibited a higher MAE rate than others (13% vs 3%, respectively, p<0.001). Recreational drugs were associated with a higher rate of in-hospital MAEs after adjustment for comorbidities (OR 8.84, 95% CI 4.68 to 16.7, p<0.001). After adjustment, cannabis, cocaine, and MDMA, assessed separately, were independently associated with in-hospital MAEs. Multiple drug detection was frequent (28% of positive patients) and associated with an even higher incidence of MAEs (OR 12.7, 95% CI 4.80 to 35.6, p<0.001). CONCLUSION The prevalence of recreational drug use in patients hospitalised in ICCU was 11%. Recreational drug detection was independently associated with worse in-hospital outcomes. CLINICAL TRIAL REGISTRATION NCT05063097.
Collapse
Affiliation(s)
- Théo Pezel
- Department of Cardiology, Hôpital Lariboisière, Assistance Publique - Hopitaux de Paris, Université Paris Cité, INSERM U 942, Paris, France
| | - Jean-Guillaume Dillinger
- Department of Cardiology, Hôpital Lariboisière, Assistance Publique - Hopitaux de Paris, Université Paris Cité, INSERM U 942, Paris, France
| | - Antonin Trimaille
- Department of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France
| | - Clément Delmas
- Intensive Cardiac Care Unit, University Hospital of Rangueil, Toulouse, France
| | - Nicolas Piliero
- Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - Claire Bouleti
- Cardiology, University of Poitiers, Clinical Investigation Center (CIC) INSERM 1402, Poitiers University Hospital, Poitiers, France
| | | | - Amine El Ouahidi
- Department of Cardiology, University Hospital of Brest, Brest, France
| | | | - Benoit Lattuca
- Cardiology, Centre Hospitalier Universitaire de Nîmes, Montpellier University, Nimes, France
| | | | - Damien Fard
- Intensive Cardiac Care Unit, Hopital Henri Mondor, Creteil, France
| | - Nathalie Noirclerc
- Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, Rhône-Alpes, France
| | - Guillaume Bonnet
- Assistance Publique Hopitaux de Marseille, Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, Provence-Alpes-Côte d'Azu, France
- Unité de Recherche Clinique, Groupe hospitalier Lariboisiere Fernand-Widal, Paris, Île-de-France, France
| | | | - Meyer Elbaz
- Intensive Cardiac Care Unit, University Hospital of Rangueil, Toulouse, France
| | - Antoine Deney
- University Hospital Centre Toulouse, Toulouse, Midi-Pyrénées, France
| | | | - Clemence Docq
- Department of Cardiology, University Hospital of Lille, Lille, France
| | - Francois Roubille
- Cardiology Department, INI-CRT, CHU de Montpellier, PhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, France
| | - Charles Fauvel
- Rouen University Hospital, INSERM EnVI 1096, Rouen, France
| | - Thomas Bochaton
- Intensive Cardiological Care Division, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France
| | - Victor Aboyans
- Department of Cardiology, Dupuytren University Hospital and Inserm 1094, Limoges, France
| | - Franck Boccara
- Cardiology, Sorbonne Université, GRC n°22, C²MV, Inserm UMR_S 938, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire de Cardio-métabolisme et Nutrition (ICAN), Assistance Publique-Hôpitaux de Paris, Hôpital Saint Antoine Service de Cardiologie, Paris, France
| | | | - Anne Batisse
- Centre d'évaluation et d'information sur la pharmacodépendence de Paris, GH Lariboisiere Fernand-Widal, Paris, Île-de-France, France
| | - Gabriel Steg
- Cardiology, Université Paris-Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, and Institut Universitaire de France, PARIS, France
| | - Eric Vicaut
- Unité de Recherche Clinique, Groupe hospitalier Lariboisiere Fernand-Widal, Paris, Île-de-France, France
| | - Patrick Henry
- Department of Cardiology, Hôpital Lariboisière, Assistance Publique - Hopitaux de Paris, Université Paris Cité, INSERM U 942, Paris, France
| |
Collapse
|
3
|
Nader V, Matta A, Kang R, Deney A, Azar R, Rouzaud-Laborde C, Kunduzova O, Itier R, Fournier P, Galinier M, Carrié D, Roncalli J. Mortality rate after coronary revascularization in heart failure patients with coronary artery disease. ESC Heart Fail 2023. [PMID: 37376752 PMCID: PMC10375079 DOI: 10.1002/ehf2.14445] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Revised: 05/21/2023] [Accepted: 06/08/2023] [Indexed: 06/29/2023] Open
Abstract
AIMS Coronary artery disease (CAD) is a common cause of heart failure (HF). It remains unclear who, when and why to direct towards coronary revascularization. The outcomes of coronary revascularization in HF patients are still a matter of debate nowadays. This study aims to evaluate the effect of revascularization strategy on all-cause of death in the context of ischaemic HF. METHODS AND RESULTS An observational cohort was conducted on 692 consecutive patients who underwent coronary angiography at the University Hospital of Toulouse between January 2018 and December 2021 for either a recent diagnosis of HF or a decompensated chronic HF, and in whom coronary angiograms showed at least 50% obstructive coronary lesion. The study population was divided into two groups according to the performance or not of a coronary revascularization procedure. The living status (alive or dead) of each of the study's participants was observed by April 2022. Seventy-three per cent of the study population underwent coronary revascularization either by percutaneous coronary intervention (66.6%) or coronary artery bypass grafting (6.2%). Baseline characteristics including age, sex and cardiovascular risk factors did not differ between the invasive and conservative groups, respectively. Death occurred in 162 study participants resulting in an all-cause mortality rate of 23.5%; 26.7% of observed deaths have occurred in the conservative group versus 22.2% in the invasive group (P = 0.208). No difference in survival outcomes has been observed over a mean follow-up period of 2.5 years (P = 0.140) even after stratification by HF categories (P = 0.132) or revascularization modalities (P = 0.366). CONCLUSIONS Findings from the present study showed comparable all-cause mortality rates between groups. Coronary revascularization does not modify short-term survival outcomes in HF patients compared with optimal medical therapy alone outside the setting of acute coronary syndrome.
Collapse
Affiliation(s)
- Vanessa Nader
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
- Faculty of Sciences, Paul-Sabatier Toulouse III University, Toulouse, France
- INSERM I2MC - UMR1297, Toulouse, France
| | - Anthony Matta
- Department of cardiology, Civilians Hospital of Colmar, Colmar, France
- Notre Dame des Secours University Hospital Center, Lebanon/School of Medicine and Medical Sciences, Holy Spirit University of Kaslik, Jounieh, Lebanon
| | - Ryeonshi Kang
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
- Faculty of Sciences, Paul-Sabatier Toulouse III University, Toulouse, France
| | - Antoine Deney
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
| | - Rania Azar
- Faculty of Pharmacy, Lebanese University, Beirut, Lebanon
| | - Charlotte Rouzaud-Laborde
- INSERM I2MC - UMR1297, Toulouse, France
- Clinical Department of Pharmacy, Faculty of Pharmacy, UFR Toulouse III, Toulouse, France
| | | | - Romain Itier
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
| | - Pauline Fournier
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
| | - Michel Galinier
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
- Faculty of Sciences, Paul-Sabatier Toulouse III University, Toulouse, France
| | - Didier Carrié
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
- Faculty of Sciences, Paul-Sabatier Toulouse III University, Toulouse, France
| | - Jerome Roncalli
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
- Faculty of Sciences, Paul-Sabatier Toulouse III University, Toulouse, France
- INSERM I2MC - UMR1297, Toulouse, France
| |
Collapse
|
4
|
Banydeen R, Eggleston R, Deney A, Monfort A, Ryu JH, Vergaro G, Castiglione V, Lairez O, Emdin M, Inamo J, Baqir M, Neviere R. Risk Stratification in Transthyretin Cardiac Amyloidosis: The Added Value of Lung Spirometry. J Clin Med 2023; 12:jcm12113684. [PMID: 37297878 DOI: 10.3390/jcm12113684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Revised: 05/21/2023] [Accepted: 05/24/2023] [Indexed: 06/12/2023] Open
Abstract
Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized disease that often results in heart failure and death. Traditionally, biological staging systems are used to stratify disease severity. Reduced aerobic capacity has recently been described as useful in identifying higher risk of cardiovascular events and death. Assessment of lung volume via simple spirometry might also hold prognostic relevance. We aimed to assess the combined prognostic value of spirometry, cardiopulmonary exercise testing (CPET) and biomarker staging in ATTR-CA patients in a multi-parametric approach. We retrospectively reviewed patient records with pulmonary function and CPET testing. Patients were followed until study endpoint (MACE: composite of heart-failure-related hospitalization and all-cause death) or censure (1 April 2022). In total, 82 patients were enrolled. Median follow-up was 9 months with 31 (38%) MACE. Impaired peak VO2 and forced vital capacity (FVC) were independent predictors of MACE-free survival, with peak VO2 < 50% and FVC < 70% defining the highest risk group (HR 26, 95% CI: 5-142, mean survival: 15 months) compared to patients with the lowest risk (peak VO2 ≥ 50% and FVC ≥ 70%). Combined peak VO2, FVC and ATTR biomarker staging significantly improved MACE prediction by 35% compared to ATTR staging alone, with 67% patients reassigned a higher risk category (p < 0.01). In conclusion, combining functional and biological markers might synergistically improve risk stratification in ATTR-CA. Integrating simple, non-invasive and easily applicable CPET and spirometry in the routine management of ATTR-CA patients might prove useful for improved risk prediction, optimized monitoring and timely introduction of newer-generation therapies.
Collapse
Affiliation(s)
- Rishika Banydeen
- Department of Clinical Research, CHU Martinique (University Hospital of Martinique), 97200 Fort de France, France
- Cardiovascular Research Team EA7525, Université des Antilles (University of the French West Indies), 97200 Fort de France, France
| | - Reid Eggleston
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN 55905, USA
| | - Antoine Deney
- Department of Cardiology, Rangueil Hospital, CHU Toulouse (University Hospital of Toulouse), 31400 Toulouse, France
| | - Astrid Monfort
- Cardiovascular Research Team EA7525, Université des Antilles (University of the French West Indies), 97200 Fort de France, France
- Department of Cardiology, CHU Martinique (University Hospital of Martinique), 97200 Fort de France, France
| | - Jay H Ryu
- Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN 55905, USA
| | - Giuseppe Vergaro
- Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanita Pubblica, 56124 Pisa, Italy
| | - Vincenzo Castiglione
- Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanita Pubblica, 56124 Pisa, Italy
| | - Olivier Lairez
- Department of Cardiology, Rangueil Hospital, CHU Toulouse (University Hospital of Toulouse), 31400 Toulouse, France
| | - Michele Emdin
- Institute of Life Sciences, ScuolaSuperioreSant'Anna, Pisa, Italy & Fondazione Toscana Gabriele Monasterio, 56124 Pisa, Italy
| | - Jocelyn Inamo
- Cardiovascular Research Team EA7525, Université des Antilles (University of the French West Indies), 97200 Fort de France, France
- Department of Cardiology, CHU Martinique (University Hospital of Martinique), 97200 Fort de France, France
| | - Misbah Baqir
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN 55905, USA
| | - Remi Neviere
- Cardiovascular Research Team EA7525, Université des Antilles (University of the French West Indies), 97200 Fort de France, France
- Department of Cardiology, CHU Martinique (University Hospital of Martinique), 97200 Fort de France, France
| |
Collapse
|
5
|
Karsenty C, Guilbeau-Frugier C, Genet G, Seguelas MH, Alzieu P, Cazorla O, Montagner A, Blum Y, Dubroca C, Maupoint J, Tramunt B, Cauquil M, Sulpice T, Richard S, Arcucci S, Flores-Flores R, Pataluch N, Montoriol R, Sicard P, Deney A, Couffinhal T, Senard JM, Galés C. Ephrin-B1 regulates the adult diastolic function through a late postnatal maturation of cardiomyocyte surface crests. eLife 2023; 12:e80904. [PMID: 36649053 PMCID: PMC9844986 DOI: 10.7554/elife.80904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Accepted: 12/30/2022] [Indexed: 01/15/2023] Open
Abstract
The rod-shaped adult cardiomyocyte (CM) harbors a unique architecture of its lateral surface with periodic crests, relying on the presence of subsarcolemmal mitochondria (SSM) with unknown role. Here, we investigated the development and functional role of CM crests during the postnatal period. We found in rodents that CM crest maturation occurs late between postnatal day 20 (P20) and P60 through both SSM biogenesis, swelling and crest-crest lateral interactions between adjacent CM, promoting tissue compaction. At the functional level, we showed that the P20-P60 period is dedicated to the improvement of relaxation. Interestingly, crest maturation specifically contributes to an atypical CM hypertrophy of its short axis, without myofibril addition, but relying on CM lateral stretching. Mechanistically, using constitutive and conditional CM-specific knock-out mice, we identified ephrin-B1, a lateral membrane stabilizer, as a molecular determinant of P20-P60 crest maturation, governing both the CM lateral stretch and the diastolic function, thus highly suggesting a link between crest maturity and diastole. Remarkably, while young adult CM-specific Efnb1 KO mice essentially exhibit an impairment of the ventricular diastole with preserved ejection fraction and exercise intolerance, they progressively switch toward systolic heart failure with 100% KO mice dying after 13 months, indicative of a critical role of CM-ephrin-B1 in the adult heart function. This study highlights the molecular determinants and the biological implication of a new late P20-P60 postnatal developmental stage of the heart in rodents during which, in part, ephrin-B1 specifically regulates the maturation of the CM surface crests and of the diastolic function.
Collapse
Affiliation(s)
- Clement Karsenty
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
- Department of Pediatric Cardiology, Centre Hospitalier Universitaire de ToulouseToulouseFrance
| | - Celine Guilbeau-Frugier
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
- Department of Forensic Medicine, Centre Hospitalier Universitaire de Toulouse, Université de ToulouseToulouseFrance
| | - Gaël Genet
- Department of Cell Biology, University of Virginia School of MedicineCharlottesvilleUnited States
| | - Marie-Helene Seguelas
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
| | - Philippe Alzieu
- Université de Bordeaux, INSERM, Biologie des maladies cardiovasculairesPessacFrance
| | - Olivier Cazorla
- Université de Montpellier, INSERM, CNRS, PhyMedExpMontpellierFrance
| | - Alexandra Montagner
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
| | - Yuna Blum
- IGDR UMR 6290, CNRS, Université de Rennes 1RennesFrance
| | | | | | - Blandine Tramunt
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
- Department of Diabetology, Metabolic Diseases & Nutrition, Centre Hospitalier Universitaire de ToulouseToulouseFrance
| | - Marie Cauquil
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
| | | | - Sylvain Richard
- Université de Montpellier, INSERM, CNRS, PhyMedExpMontpellierFrance
| | - Silvia Arcucci
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
| | - Remy Flores-Flores
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
| | - Nicolas Pataluch
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
| | - Romain Montoriol
- Department of Forensic Medicine, Centre Hospitalier Universitaire de Toulouse, Université de ToulouseToulouseFrance
| | - Pierre Sicard
- Université de Montpellier, INSERM, CNRS, PhyMedExpMontpellierFrance
| | - Antoine Deney
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
| | - Thierry Couffinhal
- Université de Bordeaux, INSERM, Biologie des maladies cardiovasculairesPessacFrance
- Service des Maladies Cardiaques et Vasculaires, CHU de BordeauxBordeauxFrance
| | - Jean-Michel Senard
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
- Department of Clinical Pharmacology, Centre Hospitalier Universitaire de ToulouseToulouseFrance
| | - Celine Galés
- INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de ToulouseToulouseFrance
| |
Collapse
|
6
|
Gall E, Pezel T, Lattuca B, Puymirat E, Hauguel-Moreau M, Gretzinger A, Trimaille A, Léquipar A, Fauvel C, Charbonnel C, Zakine C, Bedossa M, Aboyans V, Deney A, Schurtz G, Bouleti C, Rossanaly Vasram R, Bochaton T, Dillinger JG, Henry P. Description of intensive cardiac care units (ICCU) in France in 2021: Insight from ADDICT-ICCU registry. Archives of Cardiovascular Diseases Supplements 2023. [DOI: 10.1016/j.acvdsp.2022.10.309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
7
|
Weizman O, Duceau B, Trimaille A, Pommier T, Cellier J, Geneste L, Panagides V, Marsou W, Deney A, Attou S, Delmotte T, Ribeyrolles S, Chemaly P, Karsenty C, Giordano G, Gautier A, Chaumont C, Guilleminot P, Sagnard A, Pastier J, Ezzouhairi N, Perin B, Zakine C, Levasseur T, Ma I, Chavignier D, Noirclerc N, Darmon A, Mevelec M, Sutter W, Mika D, Fauvel C, Pezel T, Waldmann V, Cohen A, Bonnet G. Machine learning-based scoring system to predict in-hospital outcomes in patients hospitalized with COVID-19. Arch Cardiovasc Dis 2022; 115:617-626. [PMID: 36376208 PMCID: PMC9595484 DOI: 10.1016/j.acvd.2022.08.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 07/19/2022] [Accepted: 08/01/2022] [Indexed: 02/01/2023]
Abstract
BACKGROUND The evolution of patients hospitalized with coronavirus disease 2019 (COVID-19) is still hard to predict, even after several months of dealing with the pandemic. AIMS To develop and validate a score to predict outcomes in patients hospitalized with COVID-19. METHODS All consecutive adults hospitalized for COVID-19 from February to April 2020 were included in a nationwide observational study. Primary composite outcome was transfer to an intensive care unit from an emergency department or conventional ward, or in-hospital death. A score that estimates the risk of experiencing the primary outcome was constructed from a derivation cohort using stacked LASSO (Least Absolute Shrinkage and Selection Operator), and was tested in a validation cohort. RESULTS Among 2873 patients analysed (57.9% men; 66.6±17.0 years), the primary outcome occurred in 838 (29.2%) patients: 551 (19.2%) were transferred to an intensive care unit; and 287 (10.0%) died in-hospital without transfer to an intensive care unit. Using stacked LASSO, we identified 11 variables independently associated with the primary outcome in multivariable analysis in the derivation cohort (n=2313), including demographics (sex), triage vitals (body temperature, dyspnoea, respiratory rate, fraction of inspired oxygen, blood oxygen saturation) and biological variables (pH, platelets, C-reactive protein, aspartate aminotransferase, estimated glomerular filtration rate). The Critical COVID-19 France (CCF) risk score was then developed, and displayed accurate calibration and discrimination in the derivation cohort, with C-statistics of 0.78 (95% confidence interval 0.75-0.80). The CCF risk score performed significantly better (i.e. higher C-statistics) than the usual critical care risk scores. CONCLUSIONS The CCF risk score was built using data collected routinely at hospital admission to predict outcomes in patients with COVID-19. This score holds promise to improve early triage of patients and allocation of healthcare resources.
Collapse
Affiliation(s)
- Orianne Weizman
- Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandoeuvre-lès-Nancy, France,Université de Paris, PARCC, INSERM, 75015 Paris, France
| | | | - Antonin Trimaille
- Nouvel Hopital Civil, Centre Hospitalier Régional Universitaire de Strasbourg, 67000 Strasbourg, France
| | - Thibaut Pommier
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France
| | - Joffrey Cellier
- Hôpital Européen Georges-Pompidou, Université de Paris, 75015 Paris, France
| | - Laura Geneste
- Centre Hospitalier Universitaire d’Amiens-Picardie, 80000 Amiens, France
| | - Vassili Panagides
- Centre Hospitalier Universitaire de Marseille, 13005 Marseille, France
| | - Wassima Marsou
- GCS-Groupement des Hôpitaux de l’Institut Catholique de Lille, Faculté de Médecine et de Maïeutique, Université Catholique de Lille, 59800 Lille, France
| | - Antoine Deney
- Centre Hospitalier Universitaire de Toulouse, 31400 Toulouse, France
| | - Sabir Attou
- Centre Hospitalier Universitaire de Caen-Normandie, 14000 Caen, France
| | - Thomas Delmotte
- Centre Hospitalier Universitaire de Reims, 51100 Reims, France
| | | | | | - Clément Karsenty
- Centre Hospitalier Universitaire de Toulouse, 31400 Toulouse, France
| | - Gauthier Giordano
- Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandoeuvre-lès-Nancy, France
| | | | - Corentin Chaumont
- Centre Hospitalier Universitaire de Rouen, FHU REMOD-VHF, 76000 Rouen, France
| | | | - Audrey Sagnard
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France
| | - Julie Pastier
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France
| | - Nacim Ezzouhairi
- Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux, France
| | - Benjamin Perin
- Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandoeuvre-lès-Nancy, France
| | - Cyril Zakine
- Clinique Saint-Gatien, 37540 Saint-Cyr-sur-Loire, France
| | - Thomas Levasseur
- Centre Hospitalier Intercommunal Fréjus-Saint-Raphaël, 83600 Fréjus, France
| | - Iris Ma
- Hôpital Européen Georges-Pompidou, Université de Paris, 75015 Paris, France
| | | | | | - Arthur Darmon
- Hôpital Bichat-Claude-Bernard, AP–HP, Université de Paris, 75018 Paris, France
| | - Marine Mevelec
- Centre Hospitalier Régional de Orléans, 45100 Orléans, France
| | - Willy Sutter
- Université de Paris, PARCC, INSERM, 75015 Paris, France
| | - Delphine Mika
- Université Paris-Saclay, Inserm, UMR-S 1180, 92296 Chatenay-Malabry, France
| | - Charles Fauvel
- Centre Hospitalier Universitaire de Rouen, FHU REMOD-VHF, 76000 Rouen, France
| | - Théo Pezel
- Hôpital Lariboisière, AP–HP, Université de Paris, 75010 Paris, France
| | - Victor Waldmann
- Université de Paris, PARCC, INSERM, 75015 Paris, France,Hôpital Européen Georges-Pompidou, Université de Paris, 75015 Paris, France
| | - Ariel Cohen
- Hôpital Saint-Antoine, 75012 Paris, France,Corresponding author. Hôpital Saint-Antoine, 184, Rue du Faubourg Saint-Antoine, 75012 Paris, France
| | - Guillaume Bonnet
- Université de Paris, PARCC, INSERM, 75015 Paris, France,Hôpital Européen Georges-Pompidou, Université de Paris, 75015 Paris, France
| | | |
Collapse
|
8
|
Banydeen R, Vergaro G, Deney A, Monfort A, Emdin M, Lairez O, Giguet AG, Inamo J, Neviere R. Restrictive spirometry pattern and abnormal cardiopulmonary response to exercise in transthyretin cardiac amyloidosis. Eur Respir J 2022; 59:13993003.02838-2021. [PMID: 34996829 DOI: 10.1183/13993003.02838-2021] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Accepted: 12/09/2021] [Indexed: 11/05/2022]
Affiliation(s)
- Rishika Banydeen
- Department of Clinical Research, CHU Martinique (University Hospital of Martinique), Fort de France, France.,Cardiovascular Research Team EA7525, Université des Antilles (University of the French West Indies), Fort de France, France
| | - Giuseppe Vergaro
- Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa and Division of Cardiology and Cardiovascular Medicine, Fondazione Toscana Gabriele Monasterio, Pisa
| | - Antoine Deney
- Department of Cardiology, Rangueil Hospital, CHU Toulouse (University Hospital of Toulouse), Toulouse, France
| | - Astrid Monfort
- Cardiovascular Research Team EA7525, Université des Antilles (University of the French West Indies), Fort de France, France.,Department of Cardiology, CHU Martinique (University Hospital of Martinique), Fort de France, France
| | - Michele Emdin
- Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa and Division of Cardiology and Cardiovascular Medicine, Fondazione Toscana Gabriele Monasterio, Pisa
| | - Olivier Lairez
- Department of Cardiology, Rangueil Hospital, CHU Toulouse (University Hospital of Toulouse), Toulouse, France
| | - Anna Gaelle Giguet
- Neuromuscular and Neurological Disease Reference Center (CeRCa), CHU Martinique (University Hospital of Martinique), Fort de France, France
| | - Jocelyn Inamo
- Cardiovascular Research Team EA7525, Université des Antilles (University of the French West Indies), Fort de France, France.,Department of Cardiology, CHU Martinique (University Hospital of Martinique), Fort de France, France
| | - Remi Neviere
- Cardiovascular Research Team EA7525, Université des Antilles (University of the French West Indies), Fort de France, France .,Department of Cardiology, CHU Martinique (University Hospital of Martinique), Fort de France, France
| |
Collapse
|
9
|
Deney A, Nader V, Matta A, Itier R, Fournier P, Lairez O, Pizzinat N, Carrié D, Boal F, Galinier M, Kunduzova O, Azar R, Roncalli J. Retrospective Study of 573 Patients with Heart Failure Evaluated for Coronary Artery Disease at Toulouse University Center, France. Med Sci Monit 2022; 28:e934804. [PMID: 34974513 PMCID: PMC8734094 DOI: 10.12659/msm.934804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Background Heart failure (HF) most commonly occurs due to ischemic heart disease from stenotic coronary artery disease (CAD). HF is classified into 3 groups based on the percentage of the ejection fraction (EF): reduced (HFrEF), mid-range (HFmrEF), and preserved (HFpEF). This retrospective study included 573 patients who presented with HF based on the evaluation of EF and were evaluated for CAD by coronary angiography before undergoing coronary angioplasty at a single center in Toulouse, France. Material/Methods This retrospective observational study included patients recently diagnosed with HF or acute decompensation of chronic HF and referred for coronary angiography at Toulouse University Hospital between January 2019 and May 2020. Results Significant CAD was found in 55.8%, 55%, and 55% of the whole population, HFpEF, and HFrEF groups, respectively. Older age, male sex, and diabetes mellitus were the main risk factors for ischemic HF. Except for age and sex, patients with ischemic HFpEF were comparable to those with non-ischemic HFpEF, unlike the ischemic HFrEF group, which had more common cardiovascular risk factors than the non-ischemic HFrEF group. The ischemic HFpEF group had an older age and higher rate of dyslipidemia than the ischemic HFrEF group. Conclusions At our center, CAD was diagnosed in more than half of patients who presented with heart failure with preserved or reduced EF. Older age and male sex were the common risk factors in patients with HFpEF and HFrEF.
Collapse
Affiliation(s)
- Antoine Deney
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
| | - Vanessa Nader
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France.,Faculty of Pharmacy, Lebanese University, Beirut, Lebanon
| | - Anthony Matta
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France.,Faculty of Medicine, Holy Spirit University of Kaslik, Kaslik, Lebanon
| | - Romain Itier
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
| | - Pauline Fournier
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
| | - Olivier Lairez
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
| | - Nathalie Pizzinat
- National Institute of Health and Medical Research (INSERM) U1297, Toulouse, France
| | - Didier Carrié
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
| | - Frédéric Boal
- National Institute of Health and Medical Research (INSERM) U1297, Toulouse, France
| | - Michel Galinier
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France
| | - Oksana Kunduzova
- National Institute of Health and Medical Research (INSERM) U1297, Toulouse, France
| | - Rania Azar
- Faculty of Pharmacy, Lebanese University, Beirut, Lebanon
| | - Jerome Roncalli
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse, France.,National Institute of Health and Medical Research (INSERM) U1297, Toulouse, France
| |
Collapse
|
10
|
Massot M, Itier R, Rico Ramirez Y, Rollin A, Fournier P, Ramis Barcelo M, Fortuny E, Torres L, Pons J, Barde L, Deney A, Roncalli J, Heine D, Peral V, Galinier M, Ripoll T, Maury P. The benefit of genetic testing using next-generation sequencing in patients with dilated cardiomyopathies: A multicentric international study. Archives of Cardiovascular Diseases Supplements 2022. [DOI: 10.1016/j.acvdsp.2021.09.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Bouisset F, Deney A, Ferrières J, Panagides V, Becker M, Riviere N, Yvorel C, Commeau P, Adjedj J, Benamer H, Bonnet G, Cayla G. Mechanical complications in ST-elevation myocardial infarction: The impact of pre-hospital delay. Int J Cardiol 2021; 345:14-19. [PMID: 34699868 DOI: 10.1016/j.ijcard.2021.10.020] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 09/26/2021] [Accepted: 10/15/2021] [Indexed: 02/02/2023]
Abstract
AIMS Mechanical complications (MC) (i.e., free wall rupture (FWR), papillary muscle rupture (PMR) and ventricular septal rupture (VSR)) are rare complications of ST- elevation acute myocardial infarction (STEMI). Incidence of MC according to pre-hospital delay remains unknown. We aimed to determine the rates of MC according to pre-hospital delay. METHODS Analysis was conducted on the MODIF registry data. Patients were allocated to four groups according to pre-hospital delay: 0 to 12 h, 12 to 24 h, 24 to 36 h and 36 to 48 h. RESULTS 6185 patients with complete data were analyzed. Mean age was 64.1 years old and 75.7% of patients were males. Eighty-three patients (1.34%) presented with MC: 44 (0.71%) experienced a FWR, 17 (0.27%) a PMR, and 22 (0.36%) a VSR. Global rates of MC were 0.82%, 1.43%, 1.24% and 5.07% in the four groups of pre-hospital delays - 0 to 12 h, 12 to 24 h, 24 to 36 h and 36 to 48 h - respectively (p < 0.001). In-hospital mortality rates were high: 44.2%, 47.1% and 54.6% for FWR, PMR and VSR, respectively. In multivariate analysis, factors independently related to the occurrence of MC were older age, female sex, simultaneous COVID-19 infection, absence of dyslipidemia, initial TIMI flow 0 or 1 in the culprit artery, 36 to 48 h-pre-hospital delay and absence of revascularization by percutaneous coronary intervention (PCI) with stent implantation. CONCLUSION The probability of MC in STEMI increases with pre-hospital delay. Mechanical complications of STEMI remain associated with a very poor prognosis.
Collapse
Affiliation(s)
- Frederic Bouisset
- Centre Hospitalier Universitaire de Toulouse, Hôpital Rangueil, Toulouse, France; Department of Epidemiology INSERM UMR 1027, Toulouse, France.
| | - Antoine Deney
- Centre Hospitalier Universitaire de Toulouse, Hôpital Rangueil, Toulouse, France
| | - Jean Ferrières
- Centre Hospitalier Universitaire de Toulouse, Hôpital Rangueil, Toulouse, France; Department of Epidemiology INSERM UMR 1027, Toulouse, France
| | - Vassili Panagides
- Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France
| | - Mathieu Becker
- CHR Metz -Thionville, Metz Hopital de Mercy, Metz, France
| | - Nicolas Riviere
- University of Bordeaux, Hôpital Cardiologique Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
| | | | | | - Julien Adjedj
- Institute Arnaud Tzanck, Saint Laurent du Var, France
| | - Hakim Benamer
- Institut Jacques Cartier, Ramsay Générale de Santé, ICPS, Massy, France
| | - Guillaume Bonnet
- University of Bordeaux, Hôpital Cardiologique Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
| | - Guillaume Cayla
- Cardiology Department, Nimes University Hospital, Montpellier University, Nimes, France
| | | |
Collapse
|
12
|
Bouchau R, Cariou E, Deney A, Belaid S, Itier R, Blanchard V, Fournier P, Duparc A, Galinier M, Carrié D, Lairez O, Lavie-Badie Y. Sports participation and myocarditis: Influence of sport types on disease severity. Int J Cardiol Heart Vasc 2021; 37:100895. [PMID: 34765717 PMCID: PMC8571161 DOI: 10.1016/j.ijcha.2021.100895] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2021] [Revised: 10/11/2021] [Accepted: 10/13/2021] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To study, in the context of acute myocarditis (AM) in sportsmen, the association between the category of sport practiced and the severity of AM. DESIGN Retrospective study. SETTING Single tertiary center. PATIENTS 82 sportspeople (≥2.5 h of sport per week) who presented an AM. ASSESSMENT OF RISK FACTORS The type of sport activity before AM were collected. MAIN OUTCOME MEASURES Complicated AM was defined by a left ventricular ejection fraction <50% or the use of inotropic drugs or ventricular assist device. RESULTS Mean age was 29 ± 9 year-old, 77 (94%) were men. Sixteen (20%) had a complicated AM. Practicing sport over 6 h a week or a Mitchell's Class IIIA sport were associated with complicated AM (44 vs. 17%, p = 0.019 and 38 vs. 11%, p = 0.008, respectively). Practicing a Mitchell's Class IC sport was associated with uncomplicated AM (6 vs. 38%, p = 0.008). CONCLUSION In sportspeople's AM, the pattern of sport activity (static or dynamic component, practice intensity) is associated with the disease's severity.
Collapse
Affiliation(s)
- Robin Bouchau
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
| | - Eve Cariou
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
| | - Antoine Deney
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
| | - Slimane Belaid
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
| | - Romain Itier
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
- Department of Cardiovascular Rehabilitation, Rangueil University Hospital, Toulouse, France
| | - Virginie Blanchard
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
- Department of Nuclear Medicine, Rangueil University Hospital, Toulouse, France
- Medical School of Toulouse, Paul Sabatier University, Toulouse, France
| | - Pauline Fournier
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
| | - Alexandre Duparc
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
| | - Michel Galinier
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
- Medical School of Toulouse, Paul Sabatier University, Toulouse, France
| | - Didier Carrié
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
- Medical School of Toulouse, Paul Sabatier University, Toulouse, France
| | - Olivier Lairez
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
- Department of Nuclear Medicine, Rangueil University Hospital, Toulouse, France
- Medical School of Toulouse, Paul Sabatier University, Toulouse, France
| | - Yoan Lavie-Badie
- Department of Cardiology, Rangueil University Hospital, Toulouse, France
- Department of Nuclear Medicine, Rangueil University Hospital, Toulouse, France
| |
Collapse
|
13
|
Trimaille A, Ribeyrolles S, Fauvel C, Chaumont C, Weizman O, Pommier T, Cellier J, Geneste L, Panagides V, Marsou W, Deney A, Attou S, Delmotte T, Chemaly P, Karsenty C, Giordano G, Gautier A, Guilleminot P, Sagnard A, Pastier J, Duceau B, Sutter W, Waldmann V, Pezel T, Mika D, Cohen A, Bonnet G. Cardiovascular Characteristics and Outcomes of Young Patients with COVID-19. J Cardiovasc Dev Dis 2021; 8:jcdd8120165. [PMID: 34940520 PMCID: PMC8704739 DOI: 10.3390/jcdd8120165] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2021] [Revised: 11/14/2021] [Accepted: 11/21/2021] [Indexed: 01/10/2023] Open
Abstract
Although 18–45-year-old (y-o) patients represent a significant proportion of patients hospitalized for COVID-19, data concerning the young population remain scarce. The Critical COVID France (CCF) study was an observational study including consecutive patients hospitalized for COVID-19 in 24 centers between 26 February and 20 April 2020. The primary composite outcome included transfer to the intensive care unit (ICU) or in-hospital death. Secondary outcomes were cardiovascular (CV) complications. Among 2868 patients, 321 (11.2%) patients were in the 18–45-y-o range. In comparison with older patients, young patients were more likely to have class 2 obesity and less likely to have hypertension, diabetes and dyslipidemia. The primary outcome occurred less frequently in 18–45-y-o patients in comparison with patients > 45 years old (y/o) (16.8% vs. 30.7%, p < 0.001). The 18–45-y-o patients presented with pericarditis (2.2% vs. 0.5%, p = 0.003) and myocarditis (2.5% vs. 0.6%, p = 0.002) more frequently than patients >45 y/o. Acute heart failure occurred less frequently in 18–45-y-o patients (0.9% vs. 7.2%, p < 0.001), while thrombotic complications were similar in young and older patients. Whereas both transfer to the ICU and in-hospital death occurred less frequently in young patients, COVID-19 seemed to have a particular CV impact in this population.
Collapse
Affiliation(s)
- Antonin Trimaille
- Centre Hospitalier Régional Universitaire de Strasbourg, 67000 Strasbourg, France;
| | | | - Charles Fauvel
- Centre Hospitalier Universitaire de Rouen, 76000 Rouen, France; (C.F.); (C.C.)
| | - Corentin Chaumont
- Centre Hospitalier Universitaire de Rouen, 76000 Rouen, France; (C.F.); (C.C.)
| | - Orianne Weizman
- Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandœuvre-Lès-Nancy, France; (O.W.); (G.G.)
| | - Thibaut Pommier
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France; (T.P.); (P.G.); (A.S.); (J.P.)
| | - Joffrey Cellier
- Hôpital Européen Georges Pompidou, Université de Paris, 75015 Paris, France; (J.C.); (W.S.); (V.W.)
| | - Laura Geneste
- Centre Hospitalier Universitaire d’Amiens-Picardie, 80000 Amiens, France;
| | - Vassili Panagides
- Centre Hospitalier Universitaire de Marseille, 13005 Marseille, France;
| | - Wassima Marsou
- Faculté de Médecine et de Maïeutique, GCS-Groupement des Hôpitaux de l’Institut Catholique de Lille, Université Catholique de Lille, 59800 Lille, France;
| | - Antoine Deney
- Centre Hospitalier Universitaire de Toulouse, 31400 Toulouse, France; (A.D.); (C.K.)
| | - Sabir Attou
- Centre Hospitalier Universitaire de Caen-Normandie, 14000 Caen, France;
| | - Thomas Delmotte
- Centre Hospitalier Universitaire de Reims, 51100 Reims, France;
| | - Pascale Chemaly
- Institut Cardiovasculaire Paris Sud, Massy, 91300 Paris, France; (P.C.); (A.G.)
| | - Clément Karsenty
- Centre Hospitalier Universitaire de Toulouse, 31400 Toulouse, France; (A.D.); (C.K.)
| | - Gauthier Giordano
- Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandœuvre-Lès-Nancy, France; (O.W.); (G.G.)
| | - Alexandre Gautier
- Institut Cardiovasculaire Paris Sud, Massy, 91300 Paris, France; (P.C.); (A.G.)
| | - Pierre Guilleminot
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France; (T.P.); (P.G.); (A.S.); (J.P.)
| | - Audrey Sagnard
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France; (T.P.); (P.G.); (A.S.); (J.P.)
| | - Julie Pastier
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France; (T.P.); (P.G.); (A.S.); (J.P.)
| | - Baptiste Duceau
- Paris Cardiovascular Research Center (PARCC), Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Université de Paris, 75015 Paris, France; (B.D.); (G.B.)
| | - Willy Sutter
- Hôpital Européen Georges Pompidou, Université de Paris, 75015 Paris, France; (J.C.); (W.S.); (V.W.)
- Paris Cardiovascular Research Center (PARCC), Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Université de Paris, 75015 Paris, France; (B.D.); (G.B.)
| | - Victor Waldmann
- Hôpital Européen Georges Pompidou, Université de Paris, 75015 Paris, France; (J.C.); (W.S.); (V.W.)
- Paris Cardiovascular Research Center (PARCC), Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Université de Paris, 75015 Paris, France; (B.D.); (G.B.)
| | - Théo Pezel
- Hôpital Lariboisière, APHP, Université de Paris, 75010 Paris, France;
| | - Delphine Mika
- Signaling and Cardiovascular Pathophysiology, Inserm, UMR-S 1180, Université Paris-Saclay, Chatenay-Malabry, 92296 Paris, France;
| | - Ariel Cohen
- Hôpital Saint Antoine, 75012 Paris, France
- Correspondence:
| | - Guillaume Bonnet
- Paris Cardiovascular Research Center (PARCC), Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Université de Paris, 75015 Paris, France; (B.D.); (G.B.)
- Unité Médico-Chirurgicale de Valvulopathies et Cardiomyopathies, Université de Bordeaux, Hopital Cardiologique Haut-Lévêque, 33600 Pessac, France
| | | |
Collapse
|
14
|
Panagides V, Vincent F, Weizman O, Jonveaux M, Trimaille A, Pommier T, Cellier J, Geneste L, Marsou W, Deney A, Attou S, Delmotte T, Fauvel C, Ezzouhairi N, Perin B, Zakine C, Levasseur T, Ma I, Chavignier D, Noirclerc N, Darmon A, Mevelec M, Karsenty C, Duceau B, Sutter W, Mika D, Pezel T, Waldmann V, Ternacle J, Cohen A, Bonnet G. History of heart failure in patients with coronavirus disease 2019: Insights from a French registry. Arch Cardiovasc Dis 2021; 114:415-425. [PMID: 34099379 PMCID: PMC8141712 DOI: 10.1016/j.acvd.2021.04.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 04/20/2021] [Accepted: 04/27/2021] [Indexed: 12/14/2022]
Abstract
BACKGROUND Although cardiovascular comorbidities seem to be strongly associated with worse outcomes in patients with coronavirus disease 2019 (COVID-19), data regarding patients with preexisting heart failure are limited. AIMS To investigate the incidence, characteristics and clinical outcomes of patients with COVID-19 with a history of heart failure with preserved or reduced ejection fraction. METHODS We performed an observational multicentre study including all patients hospitalized for COVID-19 across 24 centres in France from 26 February to 20 April 2020. The primary endpoint was a composite of in-hospital death or need for orotracheal intubation. RESULTS Overall, 2809 patients (mean age 66.4±16.9years) were included. Three hundred and seventeen patients (11.2%) had a history of heart failure; among them, 49.2% had heart failure with reduced ejection fraction and 50.8% had heart failure with preserved ejection fraction. COVID-19 severity at admission, defined by a quick sequential organ failure assessment score>1, was similar in patients with versus without a history of heart failure. Before and after adjustment for age, male sex, cardiovascular comorbidities and quick sequential organ failure assessment score, history of heart failure was associated with the primary endpoint (hazard ratio [HR]: 1.41, 95% confidence interval [CI]: 1.06-1.90; P=0.02). This result seemed to be mainly driven by a history of heart failure with preserved ejection fraction (HR: 1.61, 95% CI: 1.13-2.27; P=0.01) rather than heart failure with reduced ejection fraction (HR: 1.19, 95% CI: 0.79-1.81; P=0.41). CONCLUSIONS History of heart failure in patients with COVID-19 was associated with a higher risk of in-hospital death or orotracheal intubation. These findings suggest that patients with a history of heart failure, particularly heart failure with preserved ejection fraction, should be considered at high risk of clinical deterioration.
Collapse
Affiliation(s)
- Vassili Panagides
- Aix-Marseille Université, Intensive Care Unit, Hôpital Nord, AP-HM, 13015 Marseille, France
| | - Flavien Vincent
- Centre Hospitalier Universitaire de Lille, Institut Cœur Poumon, Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, INSERM U1011, Institut Pasteur de Lille, EGID, Université de Lille, 59800 Lille, France
| | - Orianne Weizman
- Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, 54500 Vandœuvre-les-Nancy, France; Université de Paris, Paris Cardiovascular Research Centre (PARCC), INSERM, UMR-S970, 75015 Paris, France
| | - Melchior Jonveaux
- Département de Cardiologie, Expert Valve Center, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, 94010 Créteil, France
| | - Antonin Trimaille
- Nouvel Hôpital Civil, Centre Hospitalier Régional Universitaire de Strasbourg, 67000 Strasbourg, France
| | - Thibaut Pommier
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France
| | - Joffrey Cellier
- Hôpital Européen Georges-Pompidou, Université de Paris, 75015 Paris, France
| | - Laura Geneste
- Centre Hospitalier Universitaire d'Amiens-Picardie, 80000 Amiens, France
| | - Wassima Marsou
- GCS-Groupement des Hôpitaux de l'Institut Catholique de Lille, Faculté de Médecine et de Maïeutique, Université Catholique de Lille, 59800 Lille, France
| | - Antoine Deney
- Centre Hospitalier Universitaire de Toulouse, 31400 Toulouse, France
| | - Sabir Attou
- Centre Hospitalier Universitaire de Caen-Normandie, 14000 Caen, France
| | - Thomas Delmotte
- Centre Hospitalier Universitaire de Reims, 51100 Reims, France
| | - Charles Fauvel
- Rouen University Hospital, FHU REMOD-VHF, 76000 Rouen, France
| | - Nacim Ezzouhairi
- University of Bordeaux, Hôpital Cardiologique Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
| | - Benjamin Perin
- Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, 54500 Vandœuvre-les-Nancy, France
| | - Cyril Zakine
- Clinique Saint-Gatien, 37540 Saint-Cyr-sur-Loire, France
| | - Thomas Levasseur
- Centre Hospitalier Intercommunal Fréjus-Saint-Raphaël, 83600 Fréjus, France
| | - Iris Ma
- Hôpital Européen Georges-Pompidou, Université de Paris, 75015 Paris, France
| | | | | | - Arthur Darmon
- Hôpital Bichat-Claude-Bernard, AP-HP, Université de Paris, 75018 Paris, France
| | - Marine Mevelec
- Centre Hospitalier Annecy Genevois, 74370 Épagny-Metz-Tessy, France
| | - Clément Karsenty
- Centre Hospitalier Universitaire de Toulouse, 31400 Toulouse, France
| | - Baptiste Duceau
- Département de Cardiologie, Expert Valve Center, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, 94010 Créteil, France
| | - Willy Sutter
- Département de Cardiologie, Expert Valve Center, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, 94010 Créteil, France
| | - Delphine Mika
- Université Paris-Saclay, INSERM, UMR-S 1180, 92296 Châtenay-Malabry, France
| | - Théo Pezel
- Hôpital Lariboisière, AP-HP, University of Paris, 75010 Paris, France
| | - Victor Waldmann
- Département de Cardiologie, Expert Valve Center, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, 94010 Créteil, France
| | - Julien Ternacle
- University of Bordeaux, Hôpital Cardiologique Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France; Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval/Québec Heart and Lung Institute, Laval University, Québec G1V 4G5, Canada
| | | | - Guillaume Bonnet
- Université de Paris, Paris Cardiovascular Research Centre (PARCC), INSERM, UMR-S970, 75015 Paris, France; University of Bordeaux, Hôpital Cardiologique Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
| | | |
Collapse
|
15
|
Weizman O, Mika D, Cellier J, Geneste L, Trimaille A, Pommier T, Panagides V, Marsou W, Deney A, Attou S, Delmotte T, Ribeyrolles S, Chemaly P, Karsenty C, Giordano G, Gautier A, Chaumont C, Guilleminot P, Sagnard A, Pastier J, Duceau B, Sutter W, Fauvel C, Pezel T, Bonnet G, Cohen A, Waldmann V. Characteristics and impact of cardiovascular comorbidities on coronavirus disease 2019 in women: A multicentre cohort study. Arch Cardiovasc Dis 2021; 114:394-406. [PMID: 34154954 PMCID: PMC8139232 DOI: 10.1016/j.acvd.2021.04.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 03/23/2021] [Accepted: 04/13/2021] [Indexed: 01/10/2023]
Abstract
Background Although women account for up to half of patients hospitalized for coronavirus disease 2019 (COVID-19), no specific data have been reported in this population. Aims To assess the burden and impact of cardiovascular comorbidities in women with COVID-19. Methods All consecutive patients hospitalized for COVID-19 across 24 hospitals from 26 February to 20 April 2020 were included. The primary composite outcome was transfer to an intensive care unit or in-hospital death. Results Among 2878 patients, 1212 (42.1%) were women. Women were older (68.3 ± 18.0 vs. 65.4 ± 16.0 years; P < 0.001), but had less prevalent cardiovascular comorbidities than men. Among women, 276 (22.8%) experienced the primary outcome, including 161 (13.3%) transfers to an intensive care unit and 115 (9.5%) deaths without transfer to intensive care unit. The rate of in-hospital death or transfer to an intensive care unit was lower in women versus men (crude hazard ratio [HR]: 0.62, 95% confidence interval [CI]: 0.53–0.72). Age (adjusted HR: 1.05 per 5-year increase, 95% CI: 1.01–1.10), body mass index (adjusted HR: 1.06 per 2-unit increase, 95% CI: 1.02–1.10), chronic kidney disease (adjusted HR: 1.57, 95% CI: 1.11–2.22) and heart failure (adjusted HR: 1.52, 95% CI: 1.04–2.22) were independently associated with the primary outcome in women. Elevated B-type natriuretic peptide/N-terminal prohormone of B-type natriuretic peptide (adjusted HR: 2.41, 95% CI: 1.70–3.44) and troponin (adjusted HR: 2.00, 95% CI: 1.39–2.88) concentrations at admission were also associated with the primary outcome, even in women free of previous coronary artery disease or heart failure. Conclusions Although female sex was associated with a lower risk of transfer to an intensive care unit or in-hospital death, COVID-19 remained associated with considerable morbimortality in women, especially in those with cardiovascular diseases.
Collapse
Affiliation(s)
- Orianne Weizman
- Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandœuvre-Les-Nancy, France; Université de Paris, PARCC, INSERM, 75015 Paris, France
| | - Delphine Mika
- Université Paris-Saclay, INSERM, UMR-S 1180, 92296 Châtenay-Malabry, France
| | - Joffrey Cellier
- Hôpital Européen Georges-Pompidou, AP-HP, Université de Paris, 75015 Paris, France
| | - Laura Geneste
- Centre Hospitalier Universitaire d'Amiens-Picardie, 80000 Amiens, France
| | - Antonin Trimaille
- Nouvel Hôpital Civil, Centre Hospitalier Régional Universitaire de Strasbourg, 67000 Strasbourg, France
| | - Thibaut Pommier
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France
| | - Vassili Panagides
- Centre Hospitalier Universitaire de Marseille, 13005 Marseille, France
| | - Wassima Marsou
- GCS-Groupement des Hôpitaux de l'Institut Catholique de Lille, Faculté de Médecine et de Maïeutique, Université Catholique de Lille, Lille, France
| | - Antoine Deney
- Centre Hospitalier Universitaire de Toulouse, 31400 Toulouse, France
| | - Sabir Attou
- Centre Hospitalier Universitaire de Caen-Normandie, 14000 Caen, France
| | - Thomas Delmotte
- Centre Hospitalier Universitaire de Reims, 51100 Reims, France
| | | | | | - Clément Karsenty
- Centre Hospitalier Universitaire de Toulouse, 31400 Toulouse, France
| | - Gauthier Giordano
- Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandœuvre-Les-Nancy, France
| | | | | | | | - Audrey Sagnard
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France
| | - Julie Pastier
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France
| | | | - Willy Sutter
- Université de Paris, PARCC, INSERM, 75015 Paris, France
| | - Charles Fauvel
- Rouen University Hospital, FHU REMOD-VHF, 76000 Rouen, France
| | - Théo Pezel
- Hôpital Lariboisiere, AP-HP, University of Paris, 75010 Paris, France
| | - Guillaume Bonnet
- Université de Paris, PARCC, INSERM, 75015 Paris, France; University of Bordeaux, Hôpital Cardiologique Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
| | - Ariel Cohen
- Hôpital Saint-Antoine, AP-HP, 75012 Paris, France.
| | - Victor Waldmann
- Université de Paris, PARCC, INSERM, 75015 Paris, France; Hôpital Européen Georges-Pompidou, AP-HP, Université de Paris, 75015 Paris, France
| | | |
Collapse
|
16
|
Soulat-Dufour L, Fauvel C, Weizman O, Barbe T, Pezel T, Mika D, Cellier J, Geneste L, Panagides V, Marsou W, Deney A, Attou S, Delmotte T, Ribeyrolles S, Chemaly P, Karsenty C, Giordano G, Gautier A, Duceau B, Sutter W, Chaumont C, Guilleminot P, Sagnard A, Pastier J, Trimaille A, Bonnet G, Canu M, Coisne A, Cohen A. Prognostic value of right ventricular dilatation in patients with COVID-19: a multicentre study. Eur Heart J Cardiovasc Imaging 2021; 23:569-577. [PMID: 34008835 PMCID: PMC8600376 DOI: 10.1093/ehjci/jeab067] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Accepted: 03/30/2021] [Indexed: 02/07/2023] Open
Abstract
Aims Although cardiac involvement has prognostic significance in coronavirus disease 2019 (COVID-19) and is associated with severe forms, few studies have explored the prognostic role of transthoracic echocardiography (TTE). We investigated the link between TTE parameters and prognosis in COVID-19. Methods and results Consecutive patients with COVID-19 admitted to 24 French hospitals were retrospectively included. Comprehensive data, including clinical and biological parameters, were recorded at admission. Focused TTE was performed during hospitalization, according to clinical indication. Patients were followed for a primary composite outcome of death or transfer to intensive care unit (ICU) during hospitalization. Among 2878 patients, 445 (15%) underwent TTE. Most of these had cardiovascular risk factors, a history of cardiovascular disease, and were on cardiovascular treatments. Dilatation and dysfunction were observed in, respectively, 12% (48/412) and 23% (102/442) of patients for the left ventricle, and in 12% (47/407) and 16% (65/402) for the right ventricle (RV). Primary composite outcome occurred in 44% (n = 196) of patients [9% (n = 42) for death without ICU transfer and 35% (n = 154) for admission to ICU]. RV dilatation was the only TTE parameter associated with the primary outcome. After adjustment, male sex [hazard ratio (HR) 1.56, 95% confidence interval (CI) 1.09 − 2.25; P = 0.02], higher body mass index (HR 1.10, 95% CI 1.02 − 1.18; P = 0.01), anticoagulation (HR 0.53, 95% CI 0.33 − 0.86; P = 0.01), and RV dilatation (HR 1.66, 95% CI 1.05 − 2.64; P = 0.03) remained independently associated with the primary outcome. Conclusion Echocardiographic evaluation of RV dilatation could be useful for assessing risk of severe COVID-19 developing in hospitalized patients.
Collapse
Affiliation(s)
- Laurie Soulat-Dufour
- Department of Cardiology, Saint Antoine and Tenon Hospital, AP-HP, INSERM UMRS-ICAN 1166 and Sorbonne Université, Paris, France
| | - Charles Fauvel
- Department of Cardiology, Rouen University Hospital, FHU REMOD-VHF, F76000 Rouen, France
| | - Orianne Weizman
- Department of Cardiology, Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandoeuvre-Les-Nancy, France.,Université de Paris, PARCC, INSERM, 75015 Paris, France
| | - Thomas Barbe
- Department of Cardiology, Rouen University Hospital, FHU REMOD-VHF, F76000 Rouen, France
| | - Théo Pezel
- Department of Cardiology, Lariboisiere Hospital, APHP, University of Paris, 75010 Paris, France
| | - Delphine Mika
- Université Paris-Saclay, Inserm, UMR-S 1180, 92296 Chatenay-Malabry, France
| | - Joffrey Cellier
- Department of Cardiology, Hôpital Européen Georges Pompidou, Université de Paris, 75015 Paris, France
| | - Laura Geneste
- Department of Cardiology, Centre Hospitalier Universitaire d'Amiens-Picardie, 80000 Amiens, France
| | - Vassili Panagides
- Department of Cardiology, Aix-Marseille Université, Intensive care unit, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France
| | - Wassima Marsou
- Department of Cardiology, GCS-Groupement des Hôpitaux de l'Institut Catholique de Lille, Faculté de Médecine et de Maïeutique, Université Catholique de Lille, Lille, France
| | - Antoine Deney
- Departement of Cardiology, Rangueil University Hospital, Toulouse, France" et "Institute of Cardiovascular and Metabolic Diseases, National Institute of Health and Medical Research (INSERM), UMR-1048 Toulouse, France
| | - Sabir Attou
- Department of Cardiology, Centre Hospitalier Universitaire de Caen-Normandie, 14000 Caen, France
| | - Thomas Delmotte
- Department of Cardiology, Centre Hospitalier Universitaire de Reims, 51100 Reims, France
| | - Sophie Ribeyrolles
- Department of Cardiology, Institut Mutualiste Montsouris, 75014 Paris, France
| | - Pascale Chemaly
- Department of Cardiology, Institut Cardiovasculaire Paris Sud, 91300 Massy, France
| | - Clement Karsenty
- Paediatric and Congenital Cardiology, Children's Hospital, CHU Toulouse, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse University, France
| | - Gauthier Giordano
- Department of Cardiology, Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandoeuvre-Les-Nancy, France
| | - Alexandre Gautier
- Department of Cardiology, Institut Cardiovasculaire Paris Sud, 91300 Massy, France
| | | | - Willy Sutter
- Université de Paris, PARCC, INSERM, 75015 Paris, France
| | - Corentin Chaumont
- Department of Cardiology, Rouen University Hospital, FHU REMOD-VHF, F76000 Rouen, France
| | - Pierre Guilleminot
- Department of Cardiology, Centre Hospitalier Universitaire de Dijon, 21079 Dijon, France
| | - Audrey Sagnard
- Department of Cardiology, Centre Hospitalier Universitaire de Dijon, 21079 Dijon, France
| | - Julie Pastier
- Paediatric and Congenital Cardiology, Children's Hospital, CHU Toulouse, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse University, France
| | - Antonin Trimaille
- Department of Cardiology, Nouvel Hôpital Civil, Centre Hospitalier Régional Universitaire de Strasbourg, 67000 Strasbourg, France
| | - Guillaume Bonnet
- Université de Paris, PARCC, INSERM, 75015 Paris, France.,Department of Cardiology, Hôpital Européen Georges Pompidou, Université de Paris, 75015 Paris, France
| | - Marjorie Canu
- Department of Cardiology, University Hospital, CHU Grenoble, BP 217, 38043 Grenoble Cedex 09, France
| | - Augustin Coisne
- CHU Lille, Department of Clinical Physiology and Echocardiography-Heart Valve Center. University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France
| | - Ariel Cohen
- Department of Cardiology, Saint Antoine and Tenon Hospital, AP-HP, INSERM UMRS-ICAN 1166 and Sorbonne Université, Paris, France
| |
Collapse
|
17
|
Bonnet G, Panagides V, Becker M, Rivière N, Yvorel C, Deney A, Lattuca B, Duband B, Moussa K, Juenin L, Pamart T, Semaan C, Uhry S, Noirclerc N, Vincent F, Vignac M, Palermo V, Martin AS, Zeitouni M, Van Belle E, Tirouvanziam A, Manchuelle A, Chamandi C, Kerneis M, Boukantar M, Belle L, De Poli F, Angoulvant D, Meneveau N, Robin M, Pansieri M, Bonello L, Motreff P, Bouisset F, Isaaz K, Cetran L, Khalife K, Lesizza P, Adjedj J, Benamer H, Cayla G. ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in France. Arch Cardiovasc Dis 2021; 114:340-351. [PMID: 33926830 PMCID: PMC9056233 DOI: 10.1016/j.acvd.2021.01.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Revised: 01/11/2021] [Accepted: 01/18/2021] [Indexed: 12/27/2022]
Abstract
BACKGROUND Systems of care have been challenged to control progression of the COVID-19 pandemic. Whether this has been associated with delayed reperfusion and worse outcomes in French patients with ST-segment elevation myocardial infarction (STEMI) is unknown. AIM To compare the rate of STEMI admissions, treatment delays, and outcomes between the first peak of the COVID-19 pandemic in France and the equivalent period in 2019. METHODS In this nationwide French survey, data from consecutive STEMI patients from 65 centres referred for urgent revascularization between 1 March and 31 May 2020, and between 1 March and 31 May 2019, were analysed. The primary outcome was a composite of in-hospital death or non-fatal mechanical complications of acute myocardial infarction. RESULTS A total of 6306 patients were included. During the pandemic peak, a 13.9±6.6% (P=0.003) decrease in STEMI admissions per week was observed. Delays between symptom onset and percutaneous coronary intervention were longer in 2020 versus 2019 (270 [interquartile range 150-705] vs 245 [140-646]min; P=0.013), driven by the increase in time from symptom onset to first medical contact (121 [60-360] vs 150 [62-420]min; P=0.002). During 2020, a greater number of mechanical complications was observed (0.9% vs 1.7%; P=0.029) leading to a significant difference in the primary outcome (112 patients [5.6%] in 2019 vs 129 [7.6%] in 2020; P=0.018). No significant difference was observed in rates of orotracheal intubation, in-hospital cardiac arrest, ventricular arrhythmias and cardiogenic shock. CONCLUSIONS During the first peak of the COVID-19 pandemic in France, there was a decrease in STEMI admissions, associated with longer ischaemic time, exclusively driven by an increase in patient-related delays and an increase in mechanical complications. These findings suggest the need to encourage the population to seek medical help in case of symptoms.
Collapse
Affiliation(s)
- Guillaume Bonnet
- Université de Paris, Paris Cardiovascular Research Center (PARCC), INSERM, UMR-S970, 75015 Paris, France
| | - Vassili Panagides
- Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, 13015 Marseille, France
| | - Mathieu Becker
- CHR Metz -Thionville, Metz Hôpital de Mercy, 57530 Metz, France
| | - Nicolas Rivière
- University of Bordeaux, Cardio-thoracic intensive care unit, CHU de Bordeaux, 33600 Pessac, France
| | - Cédric Yvorel
- Cardiology Department, CHU de Saint Etienne, 42270 Saint Priest-en-Jarez, France
| | - Antoine Deney
- Cardiology Department, Rangueil University Hospital, 31400 Toulouse, France
| | - Benoit Lattuca
- Cardiology Department, Nimes University Hospital, Montpellier University, 30029 Nîmes, France
| | - Benjamin Duband
- Cardiology Department, University Hospital Gabriel Montpied, 63000 Clermont-Ferrand, France
| | - Karim Moussa
- Cardiology Department, Avignon Hôpital Center, 84140 Avignon, France
| | - Léa Juenin
- Cardiology Department, University Hospital of Montpellier, University of Montpellier, 34000 Montpellier, France
| | - Thibault Pamart
- University of Burgundy Franche-Comté, EA3920, University Hospital Besancon, 25000 Besançon, France
| | - Carl Semaan
- Cardiology Department, University Hospital of Tours, 37000 Tours, France
| | - Sabrina Uhry
- Cardiology Department, CH de Haguenau, 67500 Haguenau, France
| | | | | | - Maxime Vignac
- Université de Paris, Paris Cardiovascular Research Center (PARCC), INSERM, UMR-S970, 75015 Paris, France
| | - Vincenzo Palermo
- Cardiology Department, Marie Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - Anne Sophie Martin
- CHU Henri Mondor, Service de cardiologie interventionnelle, AP-HP, 94010 Créteil, France
| | - Michel Zeitouni
- Sorbonne Université, ACTION Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), 75013 Paris, France
| | | | | | | | - Chekrallah Chamandi
- Cardiology Department, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Université de Paris, INSERM U970, 75015 Paris, France
| | - Mathieu Kerneis
- Sorbonne Université, ACTION Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), 75013 Paris, France
| | - Madjid Boukantar
- CHU Henri Mondor, Service de cardiologie interventionnelle, AP-HP, 94010 Créteil, France
| | - Loïc Belle
- Centre Hospitalier Annecy Genevois, 74370 Epagny Metz-Tessy, France
| | - Fabien De Poli
- Cardiology Department, CH de Haguenau, 67500 Haguenau, France
| | - Denis Angoulvant
- Cardiology Department, University Hospital of Tours, 37000 Tours, France
| | - Nicolas Meneveau
- University of Burgundy Franche-Comté, EA3920, University Hospital Besancon, 25000 Besançon, France
| | - Marie Robin
- Cardiology Department, University Hospital of Montpellier, University of Montpellier, 34000 Montpellier, France
| | - Michel Pansieri
- Cardiology Department, Avignon Hôpital Center, 84140 Avignon, France
| | - Laurent Bonello
- Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, 13015 Marseille, France
| | - Pascal Motreff
- Cardiology Department, University Hospital Gabriel Montpied, 63000 Clermont-Ferrand, France
| | - Frédéric Bouisset
- Cardiology Department, Rangueil University Hospital, 31400 Toulouse, France; Department of Epidemiology, INSERM UMR 1027, 31000 Toulouse, France
| | - Karl Isaaz
- Cardiology Department, CHU de Saint Etienne, 42270 Saint Priest-en-Jarez, France
| | - Laura Cetran
- University of Bordeaux, Cardio-thoracic intensive care unit, CHU de Bordeaux, 33600 Pessac, France
| | - Khalifé Khalife
- CHR Metz -Thionville, Metz Hôpital de Mercy, 57530 Metz, France
| | | | - Julien Adjedj
- Arnaud Tzanck Institute, 06700 Saint Laurent du Var, France
| | - Hakim Benamer
- Institut Jacques Cartier, Ramsay Générale de Santé, ICPS, 91300 Massy, France
| | - Guillaume Cayla
- Cardiology Department, Nimes University Hospital, Montpellier University, 30029 Nîmes, France.
| | | |
Collapse
|
18
|
Chocron R, Duceau B, Gendron N, Ezzouhairi N, Khider L, Trimaille A, Goudot G, Weizman O, Alsac JM, Pommier T, Bory O, Cellier J, Philippe A, Geneste L, Ben Abdallah I, Panagides V, El Batti S, Marsou W, Juvin P, Deney A, Messas E, Attou S, Planquette B, Mika D, Gaussem P, Fauvel C, Diehl JL, Pezel T, Mirault T, Sutter W, Sanchez O, Bonnet G, Cohen A, Smadja DM. D-dimer at hospital admission for COVID-19 are associated with in-hospital mortality, independent of venous thromboembolism: Insights from a French multicenter cohort study. Arch Cardiovasc Dis 2021; 114:381-393. [PMID: 33846096 PMCID: PMC7942155 DOI: 10.1016/j.acvd.2021.02.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 01/16/2021] [Accepted: 02/03/2021] [Indexed: 12/19/2022]
Abstract
Background Coronavirus disease 2019 (COVID-19) has been associated with coagulation disorders, in particular high concentrations of D-dimer, and increased frequency of venous thromboembolism. Aim To explore the association between D-dimer at admission and in-hospital mortality in patients hospitalised for COVID-19, with or without symptomatic venous thromboembolism. Methods From 26 February to 20 April 2020, D-dimer concentration at admission and outcomes (in-hospital mortality and venous thromboembolism) of patients hospitalised for COVID-19 in medical wards were retrospectively analysed in a multicenter study in 24 French hospitals. Results Among 2878 patients enrolled in the study, 1154 (40.1%) patients had D-dimer measurement at admission. Receiver operating characteristic curve analysis identified a D-dimer concentration > 1128 ng/mL as the best cut-off value for in-hospital mortality (area under the curve 64.9%, 95% confidence interval [CI] 60–69), with a sensitivity of 71.1% (95% CI 62–78) and a specificity of 55.6% (95% CI 52–58), which did not differ in the subgroup of patients with venous thromboembolism during hospitalisation. Among 545 (47.2%) patients with D-dimer concentration > 1128 ng/mL at admission, 86 (15.8%) deaths occurred during hospitalisation. After adjustment, in Cox proportional hazards and logistic regression models, D-dimer concentration > 1128 ng/mL at admission was also associated with a worse prognosis, with an odds ratio of 3.07 (95% CI 2.05–4.69; P < 0.001) and an adjusted hazard ratio of 2.11 (95% CI 1.31–3.4; P < 0.01). Conclusions D-dimer concentration > 1128 ng/mL is a relevant predictive factor for in-hospital mortality in patients hospitalised for COVID-19 in a medical ward, regardless of the occurrence of venous thromboembolism during hospitalisation.
Collapse
Affiliation(s)
- Richard Chocron
- Université de Paris, PARCC, INSERM; Emergency department, Georges-Pompidou European hospital, AP-HP, 75015 Paris, France.
| | | | - Nicolas Gendron
- Université de Paris, Innovative therapies in haemostasis, INSERM; Haematology department and biosurgical research laboratory (Carpentier Foundation), Georges-Pompidou European Hospital, AH-HP, 75015 Paris, France
| | - Nacim Ezzouhairi
- Université de médecine de Bordeaux, Centre hospitalier universitaire de Bordeaux, 33076 Bordeaux, France
| | - Lina Khider
- Université de Paris, Vascular medicine department and biosurgical research laboratory (Carpentier Foundation), Georges-Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Antonin Trimaille
- Nouvel hôpital civil, Centre hospitalier régional universitaire de Strasbourg, 67000 Strasbourg, France
| | - Guillaume Goudot
- Université de Paris, Vascular medicine department and biosurgical research laboratory (Carpentier Foundation), Georges-Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Orianne Weizman
- Centre hospitalier régional universitaire de Nancy, 54511 Vandœuvre-Les-Nancy, France
| | - Jean Marc Alsac
- Université de Paris, Innovative therapies in haemostasis, INSERM; Vascular surgery department and biosurgical research laboratory (Carpentier Foundation), Georges-Pompidou European Hospital, AH-HP, 75015 Paris, France
| | | | - Olivier Bory
- Université de Paris, Emergency department, Georges-Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Joffrey Cellier
- Georges-Pompidou European Hospital, AP-HP, Université de Paris, 75015 Paris, France
| | - Aurélien Philippe
- Université de Paris, Innovative therapies in haemostasis, INSERM; Haematology department and biosurgical research laboratory (Carpentier Foundation), Georges-Pompidou European Hospital, AH-HP, 75015 Paris, France
| | - Laura Geneste
- Centre hospitalier universitaire d'Amiens-Picardie, 80000 Amiens, France
| | - Iannis Ben Abdallah
- Université de Paris, Innovative therapies in haemostasis, INSERM; Vascular surgery department and biosurgical research laboratory (Carpentier Foundation), Georges-Pompidou European Hospital, AH-HP, 75015 Paris, France
| | - Vassili Panagides
- Centre hospitalier universitaire de Marseille, 13005 Marseille, France
| | - Salma El Batti
- Université de Paris, Innovative therapies in haemostasis, INSERM; Vascular surgery department and biosurgical research laboratory (Carpentier Foundation), Georges-Pompidou European Hospital, AH-HP, 75015 Paris, France
| | - Wassima Marsou
- Centre hospitalier universitaire de Lille, Université catholique de Lille, 59000 Lille, France
| | - Philippe Juvin
- Université de Paris, Emergency department, Georges-Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Antoine Deney
- Centre hospitalier universitaire de Toulouse, 31400 Toulouse, France
| | - Emmanuel Messas
- Université de Paris, PARCC, INSERM; Vascular medicine department, Georges-Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Sabir Attou
- Centre hospitalier universitaire de Caen-Normandie, 14000 Caen, France
| | - Benjamin Planquette
- Université de Paris, Innovative therapies in haemostasis, INSERM; Respiratory medicine department and biosurgical research laboratory (Carpentier Foundation), Georges-Pompidou European hospital, AH-HP, 75015 Paris, France
| | - Delphine Mika
- Université Paris-Saclay, INSERM, UMR-S 1180, 92296 Chatenay-Malabry, France
| | - Pascale Gaussem
- Université de Paris, Innovative therapies in haemostasis, INSERM; Haematology department, Georges-Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Charles Fauvel
- Rouen university hospital, FHU REMOD-VHF, 76000 Rouen, France
| | - Jean-Luc Diehl
- Université de Paris, Innovative therapies in haemostasis, INSERM; Intensive care medicine department and biosurgical research laboratory (Carpentier Foundation), Georges-Pompidou European Hospital, AH-HP, 75015 Paris, France
| | - Theo Pezel
- Lariboisière hospital, AP-HP, Université de Paris, 75010 Paris, France
| | - Tristan Mirault
- Université de Paris, PARCC, INSERM; Vascular medicine department, Georges-Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Willy Sutter
- Université de Paris, PARCC, INSERM, 75015 Paris, France
| | - Olivier Sanchez
- Université de Paris, Innovative therapies in haemostasis, INSERM; Respiratory medicine department and biosurgical research laboratory (Carpentier Foundation), Georges-Pompidou European hospital, AH-HP, 75015 Paris, France
| | | | - Ariel Cohen
- Department of cardiology, Saint-Antoine hospital, AP-HP, 75012 Paris, France
| | - David M Smadja
- Université de Paris, Innovative therapies in haemostasis, INSERM; Haematology department and biosurgical research laboratory (Carpentier Foundation), Georges-Pompidou European Hospital, AH-HP, 75015 Paris, France
| | | |
Collapse
|
19
|
Bonnet G, Weizman O, Trimaille A, Pommier T, Cellier J, Geneste L, Panagides V, Marsou W, Deney A, Attou S, Delmotte T, Ribeyrolles S, Chemaly P, Karsenty C, Giordano G, Gautier A, Chaumont C, Guilleminot P, Sagnard A, Pastiero J, Ezzouhairi N, Perin B, Zakine C, Levasseur T, Ma I, Chavignier D, Noirclerc N, Darmon A, Mevelec M, Duceau B, Sutter W, Mika D, Fauvel C, Pezel T, Waldmann V, Cohen A. Characteristics and outcomes of patients hospitalized for COVID-19 in France: The Critical COVID-19 France (CCF) study. Arch Cardiovasc Dis 2021; 114:352-363. [PMID: 34154953 PMCID: PMC7923854 DOI: 10.1016/j.acvd.2021.01.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Revised: 01/11/2021] [Accepted: 01/18/2021] [Indexed: 01/08/2023]
Abstract
Background The coronavirus disease 2019 (COVID-19) pandemic has led to a public health crisis. Only limited data are available on the characteristics and outcomes of patients hospitalized for COVID-19 in France. Aims To investigate the characteristics, cardiovascular complications and outcomes of patients hospitalized for COVID-19 in France. Methods The Critical COVID-19 France (CCF) study is a French nationwide study including all consecutive adults with a diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection hospitalized in 24 centres between 26 February and 20 April 2020. Patients admitted directly to intensive care were excluded. Clinical, biological and imaging parameters were systematically collected at hospital admission. The primary outcome was in-hospital death. Results Of 2878 patients included (mean ± SD age 66.6 ± 17.0 years, 57.8% men), 360 (12.5%) died in the hospital setting, of which 7 (20.7%) were transferred to intensive care before death. The majority of patients had at least one (72.6%) or two (41.6%) cardiovascular risk factors, mostly hypertension (50.8%), obesity (30.3%), dyslipidaemia (28.0%) and diabetes (23.7%). In multivariable analysis, older age (hazard ratio [HR] 1.05, 95% confidence interval [CI] 1.03 − 1.06; P < 0.001), male sex (HR 1.69, 95% CI 1.11 − 2.57; P = 0.01), diabetes (HR 1.72, 95% CI 1.12 − 2.63; P = 0.01), chronic kidney failure (HR 1.57, 95% CI 1.02 − 2.41; P = 0.04), elevated troponin (HR 1.66, 95% CI 1.11 − 2.49; P = 0.01), elevated B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide (HR 1.69, 95% CI 1.0004 − 2.86; P = 0.049) and quick Sequential Organ Failure Assessment score ≥ 2 (HR 1.71, 95% CI 1.12 − 2.60; P = 0.01) were independently associated with in-hospital death. Conclusions In this large nationwide cohort of patients hospitalized for COVID-19 in France, cardiovascular comorbidities and risk factors were associated with a substantial morbi-mortality burden.
Collapse
Affiliation(s)
- Guillaume Bonnet
- Université de Paris, PARCC, inserm, 75015 Paris, France; Hôpital Européen Georges-Pompidou, Université de Paris, 75015 Paris, France
| | - Orianne Weizman
- Université de Paris, PARCC, inserm, 75015 Paris, France; Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandoeuvre-Les-Nancy, France
| | - Antonin Trimaille
- Nouvel hopital Civil, Centre Hospitalier régional universitaire de Strasbourg, 67000 Strasbourg, France
| | - Thibaut Pommier
- Lariboisiere hospital, AP-HP, university of Paris, 75010 Paris, France; Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France
| | - Joffrey Cellier
- Hôpital Européen Georges-Pompidou, Université de Paris, 75015 Paris, France
| | - Laura Geneste
- Centre Hospitalier universitaire d'Amiens-Picardie, 80000 Amiens, France
| | - Vassili Panagides
- Centre Hospitalier Universitaire de Marseille, 13005 Marseille, France
| | - Wassima Marsou
- GCS-Groupement des Hôpitaux de l'Institut Catholique de Lille, Faculté de Médecine et de Maïeutique, Université Catholique de Lille, Lille, France
| | - Antoine Deney
- Centre Hospitalier universitaire de Toulouse, 31400 Toulouse, France
| | - Sabir Attou
- Centre Hospitalier universitaire de Caen-Normandie, 14000 Caen, France
| | - Thomas Delmotte
- Centre Hospitalier universitaire de Reims, 51100 Reims, France
| | | | | | - Clément Karsenty
- Centre Hospitalier universitaire de Toulouse, 31400 Toulouse, France
| | - Gauthier Giordano
- Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandoeuvre-Les-Nancy, France
| | | | | | | | - Audrey Sagnard
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France
| | - Julie Pastiero
- Centre Hospitalier Universitaire de Dijon, 21000 Dijon, France
| | - Nacim Ezzouhairi
- Centre Hospitalier universitaire de Bordeaux, 33076 Bordeaux, France
| | - Benjamin Perin
- Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandoeuvre-Les-Nancy, France
| | - Cyril Zakine
- Clinique Saint-Gatien, 37540 Saint-Cyr-sur-Loire, France
| | - Thomas Levasseur
- Centre Hospitalier intercommunal Fréjus-Saint-Raphaël, 83600 Fréjus, France
| | - Iris Ma
- Hôpital Européen Georges-Pompidou, Université de Paris, 75015 Paris, France
| | | | | | - Arthur Darmon
- Hôpital Bichat-Claude-Bernard, AP-HP, université de Paris, 75018 Paris, France
| | - Marine Mevelec
- Centre Hospitalier régional de Orléans, 45100 Orléans, France
| | - Baptiste Duceau
- Université de Paris, PARCC, inserm, 75015 Paris, France; Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandoeuvre-Les-Nancy, France
| | - Willy Sutter
- Université de Paris, PARCC, inserm, 75015 Paris, France; Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandoeuvre-Les-Nancy, France
| | - Delphine Mika
- Université Paris-Saclay, Inserm, UMR-S 1180, 92296 Chatenay-Malabry, France
| | - Charles Fauvel
- Rouen University Hospital, FHU REMOD-VHF, 76000 Rouen, France
| | - Théo Pezel
- Lariboisiere hospital, AP-HP, university of Paris, 75010 Paris, France
| | - Victor Waldmann
- Université de Paris, PARCC, inserm, 75015 Paris, France; Hôpital Européen Georges-Pompidou, Université de Paris, 75015 Paris, France
| | - Ariel Cohen
- Hôpital Saint-Antoine, Saint-Antoine and Tenon hospitals, AP-HP, Inserm UMRS-ICAN 1166 Sorbonne-Université, French Society of Cardiology 2020-2022, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France.
| |
Collapse
|
20
|
Chavarot N, Gueguen J, Bonnet G, Jdidou M, Trimaille A, Burger C, Amrouche L, Weizman O, Pommier T, Aubert O, Celier J, Sberro-Soussan R, Geneste L, Panagides V, Delahousse M, Marsou W, Aguilar C, Deney A, Zuber J, Fauvel C, Legendre C, Mika D, Pezel T, Anglicheau D, Sutter W, Zaidan M, Snanoudj R, Cohen A, Scemla A. COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. Am J Transplant 2021; 21:1285-1294. [PMID: 33252201 PMCID: PMC7753406 DOI: 10.1111/ajt.16416] [Citation(s) in RCA: 56] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Revised: 11/17/2020] [Accepted: 11/19/2020] [Indexed: 01/25/2023]
Abstract
Higher rates of severe COVID-19 have been reported in kidney transplant recipients (KTRs) compared to nontransplant patients. We aimed to determine if poorer outcomes were specifically related to chronic immunosuppression or underlying comorbidities. We used a 1:1 propensity score-matching method to compare survival and severe disease-free survival (defined as death and/or need for intensive care unit [ICU]) incidence in hospitalized KTRs and nontransplant control patients between February 26 and May 22, 2020. Patients were matched for risk factors of severe COVID-19: age, sex, body mass index, diabetes mellitus, preexisting cardiopathy, chronic lung disease, and basal renal function. We included 100 KTRs (median age [interquartile range (IQR)]) 64.7 years (55.3-73.1) in three French transplant centers. After a median follow-up of 13 days (7-30), transfer to ICU was required for 34 patients (34%) and death occurred in 26 patients (26%). Overall, 43 patients (43%) developed a severe disease during a median follow-up of 8.5 days (2-14). Propensity score matching to a large French cohort of 2017 patients hospitalized in 24 centers, revealed that survival was similar between KTRs and matched nontransplant patients with respective 30-day survival of 62.9% and 71% (p = .38) and severe disease-free 30-day survival of 50.6% and 47.5% (p = .91). These findings suggest that severity of COVID-19 in KTRs is related to their associated comorbidities and not to chronic immunosuppression.
Collapse
Affiliation(s)
- Nathalie Chavarot
- Départment de Néphrologie et transplantation rénale, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France,Université de Paris, Paris, France,Correspondence Nathalie Chavarot
| | - Juliette Gueguen
- Université de Paris, Paris, France,Paris Translational Research Centre for Organ Transplantation, PARCC, INSERM, Paris, France
| | - Guillaume Bonnet
- Université de Paris, Paris, France,Paris Translational Research Centre for Organ Transplantation, PARCC, INSERM, Paris, France
| | - Mariam Jdidou
- Département de Néphrologie et transplantation, Hôpital Foch, Suresnes
| | - Antonin Trimaille
- Nouvel Hôpital Civil, Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France
| | - Carole Burger
- Départment de Néphrologie et transplantation rénale, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France,Université de Paris, Paris, France
| | - Lucile Amrouche
- Départment de Néphrologie et transplantation rénale, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Orianne Weizman
- Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-Les-Nancy, France
| | | | - Olivier Aubert
- Université de Paris, Paris, France,Paris Translational Research Centre for Organ Transplantation, PARCC, INSERM, Paris, France
| | - Joffrey Celier
- Hôpital Européen Georges Pompidou, Université de Paris, Paris, France
| | - Rebecca Sberro-Soussan
- Départment de Néphrologie et transplantation rénale, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Laura Geneste
- Centre Hospitalier Universitaire d’Amiens-Picardie, Amiens, France
| | | | - Michel Delahousse
- Département de Néphrologie et transplantation, Hôpital Foch, Suresnes
| | - Wassima Marsou
- GCS-Groupement des Hôpitaux de l’Institut Catholique de Lille, Faculté de Médecine et de Maïeutique, Université Catholique de Lille, Lille, France
| | - Claire Aguilar
- Université de Paris, Paris, France,Départment de maladies infectieuses et tropicales, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Antoine Deney
- Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Julien Zuber
- Départment de Néphrologie et transplantation rénale, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France,Université de Paris, Paris, France
| | - Charles Fauvel
- Centre Hospitalier Universitaire de Rouen, FHU REMOD-VHF, Rouen, France
| | - Christophe Legendre
- Départment de Néphrologie et transplantation rénale, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France,Université de Paris, Paris, France
| | - Delphine Mika
- Université Paris-Saclay, Inserm, UMR-S 1180, Chatenay-Malabry, France
| | - Theo Pezel
- Hôpital Lariboisière, APHP, University of Paris, Paris, France
| | - Dany Anglicheau
- Départment de Néphrologie et transplantation rénale, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France,Université de Paris, Paris, France
| | - Willy Sutter
- Université de Paris, Paris, France,Paris Translational Research Centre for Organ Transplantation, PARCC, INSERM, Paris, France
| | - Mohamad Zaidan
- Département de Néphrologie et transplantation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Renaud Snanoudj
- Département de Néphrologie et transplantation, Hôpital Foch, Suresnes
| | - Ariel Cohen
- Université de Paris, Paris, France,Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anne Scemla
- Départment de Néphrologie et transplantation rénale, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | |
Collapse
|
21
|
Chocron R, Galand V, Cellier J, Gendron N, Pommier T, Bory O, Khider L, Trimaille A, Goudot G, Weizman O, Alsac JM, Geneste L, Schmeltz A, Panagides V, Philippe A, Marsou W, Ben Abdallah I, Deney A, El Batti S, Attou S, Juvin P, Delmotte T, Messas E, Pezel T, Planquette B, Duceau B, Gaussem P, Sutter W, Sanchez O, Waldman V, Diehl JL, Mirault T, Bonnet G, Cohen A, Smadja DM. Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID-19: Insight From a French Multicenter Cohort Study. J Am Heart Assoc 2021; 10:e018624. [PMID: 33550816 PMCID: PMC8174166 DOI: 10.1161/jaha.120.018624] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Background Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with thrombotic outcomes with coagulation and endothelial disorders. Based on that, several anticoagulation guidelines have been proposed. We aimed to determine whether anticoagulation therapy modifies the risk of developing severe COVID‐19. Methods and Results Patients with COVID‐19 initially admitted in medical wards of 24 French hospitals were included prospectively from February 26 to April 20, 2020. We used a Poisson regression model, Cox proportional hazard model, and matched propensity score to assess the effect of anticoagulation on outcomes (intensive care unit admission or in‐hospital mortality). The study enrolled 2878 patients with COVID‐19, among whom 382 (13.2%) were treated with oral anticoagulation therapy before hospitalization. After adjustment, anticoagulation therapy before hospitalization was associated with a better prognosis with an adjusted hazard ratio of 0.70 (95% CI, 0.55–0.88). Analyses performed using propensity score matching confirmed that anticoagulation therapy before hospitalization was associated with a better prognosis, with an adjusted hazard ratio of 0.43 (95% CI, 0.29–0.63) for intensive care unit admission and adjusted hazard ratio of 0.76 (95% CI, 0.61–0.98) for composite criteria intensive care unit admission or death. In contrast, therapeutic or prophylactic low‐ or high‐dose anticoagulation started during hospitalization were not associated with any of the outcomes. Conclusions Anticoagulation therapy used before hospitalization in medical wards was associated with a better prognosis in contrast with anticoagulation initiated during hospitalization. Anticoagulation therapy introduced in early disease could better prevent COVID‐19–associated coagulopathy and endotheliopathy, and lead to a better prognosis.
Collapse
Affiliation(s)
- Richard Chocron
- PARCC INSERM Université de Paris France.,Emergency Department AP-HP. CUP Georges Pompidou European Hospital Paris France
| | | | - Joffrey Cellier
- PARCC INSERM Université de Paris France.,AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Nicolas Gendron
- Innovative Therapies in Haemostasis INSERM Université de Paris France.,Hematology Department and Biosurgical Research Lab (Carpentier Foundation) AP-HP. CUP Georges Pompidou European Hospital Paris France
| | | | - Olivier Bory
- PARCC INSERM Université de Paris France.,Emergency Department AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Lina Khider
- Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation) AP-HP. CUP Georges Pompidou European HospitalUniversité de Paris France
| | - Antonin Trimaille
- Nouvel Hôpital CivilCentre Hospitalier Régional Universitaire de Strasbourg Strasbourg France
| | - Guillaume Goudot
- Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation) AP-HP. CUP Georges Pompidou European HospitalUniversité de Paris France
| | - Orianne Weizman
- PARCC INSERM Université de Paris France.,Cardiology Department AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Jean Marc Alsac
- Innovative Therapies in Haemostasis INSERM Université de Paris France.,Vascular Surgery Department and Biosurgical Research Lab (Carpentier Foundation) AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Laura Geneste
- Centre Hospitalier Universitaire d'Amiens-Picardie Amiens France
| | - Armand Schmeltz
- Emergency Department AP-HP. CUP Georges Pompidou European HospitalUniversité de Paris France
| | | | - Aurélien Philippe
- Innovative Therapies in Haemostasis INSERM Université de Paris France.,Hematology Department and Biosurgical Research Lab (Carpentier Foundation) AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Wassima Marsou
- Centre Hospitalier Universitaire de LilleUniversité Catholique de Lille France
| | - Iannis Ben Abdallah
- Innovative Therapies in Haemostasis INSERM Université de Paris France.,Vascular Surgery Department and Biosurgical Research Lab (Carpentier Foundation) AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Antoine Deney
- Centre Hospitalier Universitaire de Toulouse Toulouse France
| | - Salma El Batti
- Innovative Therapies in Haemostasis INSERM Université de Paris France.,Vascular Surgery Department and Biosurgical Research Lab (Carpentier Foundation) AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Sabir Attou
- Centre Hospitalier Universitaire de Caen-Normandie Caen France
| | - Philippe Juvin
- Emergency Department AP-HP. CUP Georges Pompidou European HospitalUniversité de Paris France
| | | | - Emmanuel Messas
- PARCC INSERM Université de Paris France.,Vascular Medicine Department AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Théo Pezel
- Lariboisiere Hospital AP-HP University of Paris France
| | - Benjamin Planquette
- Innovative Therapies in Haemostasis INSERM Université de Paris France.,Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation) AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Baptiste Duceau
- PARCC INSERM Université de Paris France.,AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Pascale Gaussem
- Innovative Therapies in Haemostasis INSERM Université de Paris France.,Hematology Department AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Willy Sutter
- PARCC INSERM Université de Paris France.,AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Olivier Sanchez
- Innovative Therapies in Haemostasis INSERM Université de Paris France.,Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation) AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Victor Waldman
- PARCC INSERM Université de Paris France.,AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Jean-Luc Diehl
- Innovative Therapies in Haemostasis INSERM Université de Paris France.,Intensive Care Medicine Department and Biosurgical Research Lab (Carpentier Foundation) AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Tristan Mirault
- PARCC INSERM Université de Paris France.,Vascular Medicine Department AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Guillaume Bonnet
- PARCC INSERM Université de Paris France.,AP-HP. CUP Georges Pompidou European Hospital Paris France
| | - Ariel Cohen
- Service de Cardiologie Unité de Cardio-Oncologie AP-HP.6 Groupe de Recherche Clinique en Cardio Oncologie Inserm 856 Hôpitaux Universitaires Paris-Est Assistance Publique-Hôpitaux de ParisHôpital Saint AntoineUniversité Pierre et Marie Curie Paris France
| | - David M Smadja
- Innovative Therapies in Haemostasis INSERM Université de Paris France.,Hematology Department and Biosurgical Research Lab (Carpentier Foundation) AP-HP. CUP Georges Pompidou European Hospital Paris France
| | | |
Collapse
|
22
|
Bouchau R, Cariou E, Belaid S, Foucque O, Cavalerie H, Moninhas M, Blanc G, Deney A, Pagezy A, Calazel P, Lairez O, Lavie-Badie Y. Sport and myocarditis: Is the way of practice as an impact on severity? Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2020.10.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Nicol M, Deney A, Lairez O, Vergaro G, Emdin M, Inamo J, Montfort A, Damy T, Harel S, Royer B, Baudet M, Cohen Solal A, Arnulf B, Logeart D. Prognostic value of cardio-pulmonary exercise testing in cardiac amyloidosis. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2020.10.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Nicol M, Deney A, Lairez O, Vergaro G, Emdin M, Carecci A, Inamo J, Montfort A, Neviere R, Damy T, Harel S, Royer B, Baudet M, Cohen-Solal A, Arnulf B, Logeart D. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. Eur J Heart Fail 2020; 23:231-239. [PMID: 33006180 DOI: 10.1002/ejhf.2016] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Revised: 08/20/2020] [Accepted: 09/26/2020] [Indexed: 12/15/2022] Open
Abstract
AIMS In amyloid patients, cardiac involvement dramatically worsens functional capacity and prognosis. We sought to study how the cardiopulmonary exercise test (CPET) could help in functional assessment and risk stratification of patients with cardiac amyloidosis (CA). METHODS AND RESULTS We carried out a multicentre study including patients with light chain (AL) or transthyretin (TTR) CA. All patients underwent exhaustive examination including CPET and follow-up. The primary prognostic endpoint was the occurrence of death or heart failure hospitalization. Overall, 150 patients were included (91 AL and 59 TTR CA). Median age, systolic blood pressure, N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin T were 70 (64-78) years, 121 [interquartile range (IQR) 109-139] mmHg, 2806 (IQR 1218-4638) ng/L and 64 (IQR 33-120) ng/L, respectively. New York Heart Association classes were I-II in 64%. Median peak oxygen consumption (VO2 ) and circulatory power were low at 13.0 (10.0-16.9) mL/kg/min and 1730 (1318-2614) mmHg/mL/min, respectively. The minute ventilation/carbon dioxide production slope was increased to 37 (IQR 33-45). A total of 77 patients (51%) had chronotropic insufficiency. After a median follow-up of 20 months, there were 37 deaths and 44 heart failure hospitalizations. At multivariate Cox analysis, peak VO2 ≤13 mL/kg/min [hazard ratio (HR) 2.7, 95% confidence interval (CI) 1.6-4.8], circulatory power ≤1730 mmHg/mL/min (HR 2.4, 95% CI 1.2-4.6) and NT-proBNP ≥1800 ng/L (HR 2.2, 95% CI 1.1-4.3) were found to be associated with the primary outcome. No events occurred in patients with both peak VO2 >13 mL/kg/min and NT-proBNP <1800 ng/L, while the association of VO2 ≤13 mL/kg/min with NT-proBNP ≥1800 ng/L identified a very high-risk subgroup. CONCLUSION In CA, CPET is helpful in assessing functional capacity, circulatory and chronotropic responses as well as the prognosis of patients along with cardiac biomarkers.
Collapse
Affiliation(s)
- Martin Nicol
- Lariboisiere Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,University of Paris, Paris, France
| | - Antoine Deney
- Rangueil Hospital, University Hospital of Toulouse, Toulouse, France
| | - Olivier Lairez
- Rangueil Hospital, University Hospital of Toulouse, Toulouse, France
| | - Giuseppe Vergaro
- Scuola Superiore Sant'Anna, Pisa, Italy.,Fondazione Toscana 'Gabriele Monasterio', Pisa, Italy
| | - Michele Emdin
- Scuola Superiore Sant'Anna, Pisa, Italy.,Fondazione Toscana 'Gabriele Monasterio', Pisa, Italy
| | | | - Jocelyn Inamo
- University Hospital of Fort de France, Fort De France, France
| | - Astrid Montfort
- University Hospital of Fort de France, Fort De France, France
| | - Remi Neviere
- University Hospital of Fort de France, Fort De France, France
| | - Thibaud Damy
- Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Creteil, France
| | - Stephanie Harel
- Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Bruno Royer
- Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Mathilde Baudet
- Lariboisiere Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Alain Cohen-Solal
- Lariboisiere Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,University of Paris, Paris, France
| | - Bertrand Arnulf
- University of Paris, Paris, France.,Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Damien Logeart
- Lariboisiere Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,University of Paris, Paris, France
| |
Collapse
|